Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 78.84% is 20% above its 5-year average of 65.87%, around the middle of its 5-year range (44.46%–94.20%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.94% above its 12-month average of 78.11%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
78.84%
RETURN ON EQUITY (ROE) AVG TTM
78.11%
RETURN ON EQUITY (ROE) AVG 3Y
65.25%
RETURN ON EQUITY (ROE) AVG 5Y
65.87%
RETURN ON EQUITY (ROE) AVG 10Y
54.86%
RETURN ON EQUITY (ROE) AVG 15Y
43.69%
RETURN ON EQUITY (ROE) AVG 20Y
35.98%
CURRENT VS TTM AVG
+0.94%
CURRENT VS 3Y AVG
+20.82%
CURRENT VS 5Y AVG
+19.69%
CURRENT VS 10Y AVG
+43.70%
CURRENT VS 15Y AVG
+80.44%
CURRENT VS 20Y AVG
+119.09%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+505.98%
vs the sector median at left
Eli Lilly and Company
Market Cap
$1.06T
Return on Equity (ROE)
78.84%
TTM Avg
78.11%
3Y Avg
65.25%
5Y Avg
65.87%
Market Cap
$647.80B
Return on Equity (ROE)
24.76%
TTM Avg
26.27%
3Y Avg
31.76%
5Y Avg
29.75%
Market Cap
$441.18B
Return on Equity (ROE)
N/A
TTM Avg
-0.29%
3Y Avg
28.74%
5Y Avg
37.53%
Market Cap
$364.36B
Return on Equity (ROE)
7.57%
TTM Avg
35.83%
3Y Avg
26.05%
5Y Avg
27.71%
Market Cap
$354.70B
Return on Equity (ROE)
14.34%
TTM Avg
14.18%
3Y Avg
19.86%
5Y Avg
21.18%
Market Cap
$342.57B
Return on Equity (ROE)
38.06%
TTM Avg
32.06%
3Y Avg
36.93%
5Y Avg
40.66%
Market Cap
$245.15B
Return on Equity (ROE)
20.79%
TTM Avg
19.16%
3Y Avg
15.60%
5Y Avg
13.86%
Market Cap
$225.75B
Return on Equity (ROE)
13.25%
TTM Avg
12.70%
3Y Avg
13.51%
5Y Avg
15.24%
Market Cap
$212.27B
Return on Equity (ROE)
74.80%
TTM Avg
79.33%
3Y Avg
111.35%
5Y Avg
101.76%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eli Lilly and Company (LLY) | $1.06T | 78.84% | 78.11% | 65.25% | 65.87% |
| Johnson & Johnson (JNJ)vs › | $647.80B | 24.76% | 26.27% | 31.76% | 29.75% |
| AbbVie Inc. (ABBV)vs › | $441.18B | N/A | -0.29% | 28.74% | 37.53% |
| Merck & Co., Inc. (MRK)vs › | $364.36B | 7.57% | 35.83% | 26.05% | 27.71% |
| UnitedHealth Group Incorporated (UNH)vs › | $354.70B | 14.34% | 14.18% | 19.86% | 21.18% |
| Roche Holding AG (RHHBY)vs › | $342.57B | 38.06% | 32.06% | 36.93% | 40.66% |
| AstraZeneca PLC (AZN)vs › | $245.15B | 20.79% | 19.16% | 15.60% | 13.86% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $225.75B | 13.25% | 12.70% | 13.51% | 15.24% |
| Amgen Inc. (AMGN)vs › | $212.27B | 74.80% | 79.33% | 111.35% | 101.76% |
| Novo Nordisk A/S (NVO)vs › | $199.51B | 53.50% | 61.58% | 67.05% | 123.42% |
ROE
78.8%
ROA
18.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 78.84% |
| 2026-03-31 | 81.01% |
| 2025-12-31 | 77.78% |
| 2025-09-30 | 77.38% |
| 2025-06-30 | 75.52% |
| 2025-03-31 | 70.45% |
| 2024-12-31 | 74.62% |
| 2024-09-30 | 58.78% |
| 2024-06-30 | 54.14% |
| 2024-03-31 | 47.91% |
| 2023-12-31 | 48.65% |
| 2023-09-30 | 44.46% |
| 2023-06-30 | 58.73% |
| 2023-03-31 | 50.82% |
| 2022-12-31 | 58.64% |
| 2022-09-30 | 59.91% |
| 2022-06-30 | 66.61% |
| 2022-03-31 | 65.69% |
| 2021-12-31 | 62.16% |
| 2021-09-30 | 76.99% |
| 2021-06-30 | 94.20% |
| 2021-03-31 | 88.31% |
| 2020-12-31 | 109.79% |
| 2020-09-30 | 115.45% |
| 2020-06-30 | 137.26% |
| 2020-03-31 | 179.72% |
| 2019-12-31 | 319.09% |
| 2019-09-30 | 234.97% |
| 2019-06-30 | 282.08% |
| 2019-03-31 | 252.24% |
| 2018-12-31 | 32.88% |
| 2018-09-30 | 3.44% |
| 2018-06-30 | -1.24% |
| 2018-03-31 | 7.74% |
| 2017-12-31 | -1.76% |
| 2017-09-30 | 14.94% |
| 2017-06-30 | 17.35% |
| 2017-03-31 | 15.58% |
| 2016-12-31 | 19.54% |
| 2016-09-30 | 15.68% |
| 2016-06-30 | 16.85% |
| 2016-03-31 | 15.45% |
| 2015-12-31 | 16.53% |
| 2015-09-30 | 15.49% |
| 2015-06-30 | 14.04% |
| 2015-03-31 | 14.69% |
| 2014-12-31 | 15.55% |
| 2014-09-30 | 15.22% |
| 2014-06-30 | 18.86% |
| 2014-03-31 | 21.07% |
| 2013-12-31 | 26.57% |
| 2013-09-30 | 28.33% |
| 2013-06-30 | 32.23% |
| 2013-03-31 | 30.94% |
| 2012-12-31 | 27.69% |
| 2012-09-30 | 25.66% |
| 2012-06-30 | 28.16% |
| 2012-03-31 | 29.01% |
| 2011-12-31 | 32.11% |
| 2011-09-30 | 30.94% |
| 2011-06-30 | 33.10% |
| 2011-03-31 | 34.99% |
| 2010-12-31 | 40.82% |
| 2010-09-30 | 38.79% |
| 2010-06-30 | 43.49% |
| 2010-03-31 | 40.76% |
| 2009-12-31 | 45.45% |
| 2009-09-30 | -2.18% |
| 2009-06-30 | -18.96% |
| 2009-03-31 | -23.61% |
| 2008-12-31 | -30.76% |
| 2008-09-30 | 17.55% |
| 2008-06-30 | 25.81% |
| 2008-03-31 | 23.53% |
| 2007-12-31 | 21.87% |
| 2007-09-30 | 17.23% |
| 2007-06-30 | 18.84% |
| 2007-03-31 | 20.26% |
| 2006-12-31 | 24.25% |
| 2006-09-30 | 24.75% |
| 2006-06-30 | 26.42% |
| 2006-03-31 | 17.77% |
| 2005-12-31 | 18.34% |
| 2005-09-30 | 11.21% |
| 2005-06-30 | 12.05% |
| 2005-03-31 | 18.51% |
| 2004-12-31 | 16.58% |
| 2004-09-30 | 22.63% |
| 2004-06-30 | 23.99% |
| 2004-03-31 | 24.19% |
| 2003-12-31 | 26.22% |
| 2003-09-30 | 26.88% |
| 2003-06-30 | 29.01% |
